I don't think a user-friendly report is any more required than a user-friendly of a biotech's efficiency and safety data needs to be user friendly. With biotechs some of us just have to rely on other analysts to dumb it down for us is all. I believe the Islechem report being difficult for armchair analysts to understand won't matter either. Smarter money with deeper pockets will understand it. And analysts with JBII on NASDAQ will help in addition to big media.